For the quarter ending 2025-06-30, APDN made $304,393 in revenue. -$19,445,607 in net income. Net profit margin of -6388.32%.
| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 304,393 | 983,374 | 1,196,617 | 877,967 |
| Cost of product revenues | 299,263 | 612,527 | 512,510 | 620,751.333 |
| Gross profit | 5,130 | 370,847 | 684,107 | 257,215.667 |
| Selling, general and administrative | 2,930,627 | 2,983,284 | 2,633,098 | 2,923,000 |
| Research and development | 768,563 | 849,358 | 1,015,010 | 893,573 |
| The amount of unrealized loss on change in fair value of warrants | - | - | - | -98,500 |
| Total operating expenses | 3,699,190 | 3,832,642 | 3,648,108 | 3,816,573 |
| The amount of loss from issuance of warrants | - | - | - | 186,694.667 |
| Loss from operations | -3,694,060 | -3,461,795 | -2,964,001 | -3,559,357.333 |
| Represents of transaction cost allocated to warrant liabilities | - | - | - | -158,299.5 |
| Other expense, net | -531 | -3,095 | -20,152 | -2,925.333 |
| Interest income | 40,267 | 60,340 | 71,440 | 46,668.667 |
| Unrealized gain on change in fair value of warrants classified as a liability | -6,410 | -68,430 | -244,000 | -1,423,333.333 |
| (loss) income before provision for income taxes | -3,647,914 | -3,336,120 | -2,668,713 | -2,979,269 |
| Net loss from continuing operations | -3,647,914 | - | - | - |
| Income tax expense (benefit) | - | - | - | 0 |
| Net loss from discontinued operations, net of tax | -336,195 | - | - | - |
| Net (loss) income | -3,984,109 | -3,336,120 | -2,668,713 | -2,979,269 |
| Less net loss attributable to noncontrolling interest | -38,746 | -31,945 | -29,301 | -21,830 |
| Net (loss) income attributable to applied dna sciences, inc | -3,945,363 | -3,304,175 | -2,639,412 | -2,957,439 |
| Deemed dividend related to warrant modifications | 15,500,244 | 23,919,429 | 14,907,223 | 58,271.75 |
| Net (loss) income attributable to common stockholders | -19,445,607 | -27,223,604 | -17,546,635 | -3,035,134.667 |
| Earnings per share, basic | -34 | -15.35 | -0.56 | -0.763 |
| Earnings per share, diluted | -34 | -15.35 | -0.56 | -0.763 |
| Weighted average number of shares outstanding, basic | 572,018 | 1,773,086 | 31,518,861 | -16,078.333 |
| Weighted average number of shares outstanding, diluted | 572,018 | 1,773,086 | 31,518,861 | -16,078.333 |
APPLIED DNA SCIENCES INC (APDN)
APPLIED DNA SCIENCES INC (APDN)